Company Overview and News
This week, Midstream stocks were little changed and basically kept pace with the S&P 500, which hit a new all-time high for the first time since January. Midstream stocks didn't get additional lift from the first positive week for oil prices in two months, but it certainly didn't hurt. Trading volume was light across midstream, with a few exceptions, and should be even lighter next week.
TGE CQP ENB WGP IPL SEP HCLP CEQP OKE.WI KMI TRP WMB EQGP AMGP EBBNF OKE KMR FGP IPPLF CVB ENBBF TRP GEIG ENB GMLP SEMG TRGP PBA KMRFZ
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
Midstream traded up for a 6th straight week, with MLPs again out front with a 2.2% total return. The MLP Index's YTD total return is now nearly 12% after being negative less than a month ago. The broad market struggled a bit, and midstream was a safe place to hide on Friday when the broad market sold off on Turkey's currency plunge.
KAAC APA KEYUF XOM SMLP IPL GBNXF EQT KMI EQGP PAA KMR PBA NFG IPPLF CVB KMRFZ FANG
The following slide deck was published by EQT GP Holdings LP in conjunction with their 2018 Q2 earnings call.
Hedge funds, private equity firms, and asset managers have flocked to the market for loans for small and midsize companies. Investors need to be wary.
WR MAIN PSEC MSCA.CL NCBS MSCA VSI EQGP TSLX AEMD PBB OCFC BBSI
17h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
17h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
19h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET